Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial
Nicholas C. Turner, Erica L. Mayer, Yeon Hee Park, Wolfgang Janni et autres
2 citationsThe Lancet Oncology